Parthenolide [20554-84-1]

Référence HY-N0141-50mg

Conditionnement : 50mg

Marque : MedChemExpress

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

Description

Parthenolide is a sesquiterpene lactone found in the medicinal herb Feverfew. Parthenolide exhibits anti-inflammatory activity by inhibiting NF-κB activation; also inhibits HDAC1 protein without affecting other class I/II HDACs.

IC50 & Target[1]

NF-κB

 

Autophagy

 

Mitophagy

 

IKKβ

 

Cellular Effect
Cell Line Type Value Description References
A-431 IC50
2.57 μM
Compound: Parthenolide
Antiproliferative activity against human A431 wild type cells measured after 72 hrs by Sulforhodamine B assay
Antiproliferative activity against human A431 wild type cells measured after 72 hrs by Sulforhodamine B assay
[PMID: 31889606]
A498 GI50
7.04 μM
Compound: 1; PTL
Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
A549 GI50
91.8 μM
Compound: 1; PTL
Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
A549 IC50
>10 μM
Compound: Parthenolide
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
[PMID: 35090346]
A549 IC50
22.03 μM
Compound: Parthenolide
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 27232656]
Bel-7402 IC50
8.62 μM
Compound: PTL
Antiproliferative activity against human Bel7402 incubated for 72 hrs by MTT assay
Antiproliferative activity against human Bel7402 incubated for 72 hrs by MTT assay
[PMID: 31553932]
Bel7402/5-FU IC50
12.98 μM
Compound: PTL
Antiproliferative activity against human Bel7402/5-FU incubated for 72 hrs by MTT assay
Antiproliferative activity against human Bel7402/5-FU incubated for 72 hrs by MTT assay
[PMID: 31553932]
Caco-2 IC50
23.4 μM
Compound: Parthenolide
Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 27232656]
CAKI-1 GI50
9.35 μM
Compound: 1; PTL
Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
CCRF-CEM GI50
9.16 μM
Compound: 1; PTL
Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
CCRF-CEM GI50
9.16 μM
Compound: Parthenolide
Growth inhibition of human CCRF-CEM cells
Growth inhibition of human CCRF-CEM cells
[PMID: 38107170]
COLO 205 GI50
14.5 μM
Compound: 1; PTL
Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
EKVX GI50
17.3 μM
Compound: 1; PTL
Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
EOL1 IC50
7.5 μM
Compound: Parthenolide
Cytotoxicity against human EOL-1 cells after 72 hrs by MTS assay
Cytotoxicity against human EOL-1 cells after 72 hrs by MTS assay
[PMID: 29350920]
HCC 2998 GI50
24.1 μM
Compound: 1; PTL
Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
HCT-116 GI50
10.8 μM
Compound: 1; PTL
Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
HCT-15 GI50
10.2 μM
Compound: 1; PTL
Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
HEK293 IC50
3.1 μM
Compound: Parthenolide
Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 27232656]
HeLa IC50
2.1 μM
Compound: Parthenolide
Cytotoxicity against human HeLa cells assessed as cell growth inhibition incubated for 68 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition incubated for 68 hrs by MTT assay
[PMID: 34665635]
HeLa IC50
23.08 μM
Compound: Parthenolide
Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 27232656]
HepG2 IC50
5.6 μM
Compound: Parthenolide
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 68 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 68 hrs by MTT assay
[PMID: 34665635]
HL-60(TB) GI50
5.71 μM
Compound: 1; PTL
Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
HOP-62 GI50
49 μM
Compound: 1; PTL
Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
HOP-92 GI50
13.5 μM
Compound: 1; PTL
Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
HT-29 GI50
23.5 μM
Compound: 1; PTL
Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
IGROV-1 GI50
21.1 μM
Compound: 1; PTL
Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
K562 GI50
22.6 μM
Compound: 1; PTL
Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
KM12 GI50
16.2 μM
Compound: 1; PTL
Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
LOX IMVI GI50
8.24 μM
Compound: 1; PTL
Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
Malme-3M GI50
13.8 μM
Compound: 1; PTL
Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
MCF7 GI50
16.4 μM
Compound: 1; PTL
Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
MCF7 IC50
>20 μM
Compound: Parthenolide
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay
[PMID: 35665692]
MCF7 IC50
27.71 μM
Compound: Parthenolide
Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 27232656]
MCF7 IC50
5.8 μM
Compound: PTD
Growth inhibition of human MCF7 cells measured after 24 hrs by SRB assay
Growth inhibition of human MCF7 cells measured after 24 hrs by SRB assay
[PMID: 27448920]
MDA-MB-231 IC50
4.36 μM
Compound: Parthenolide
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 27232656]
MEC1 EC50
6.2 μM
Compound: 1; PTL
Antiproliferative activity against human MEC1 cells assessed as reduction in cell viability by alamar blue assay
Antiproliferative activity against human MEC1 cells assessed as reduction in cell viability by alamar blue assay
[PMID: 32952998]
MOLM-13 IC50
10 μM
Compound: Parthenolide
Cytotoxicity against human MOLM13 cells after 72 hrs by MTS assay
Cytotoxicity against human MOLM13 cells after 72 hrs by MTS assay
[PMID: 29350920]
MOLT-4 GI50
14.3 μM
Compound: 1; PTL
Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
NCI/ADR-RES GI50
15 μM
Compound: 1; PTL
Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
NCI-H226 GI50
20.5 μM
Compound: 1; PTL
Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
NCI-H23 GI50
20.2 μM
Compound: 1; PTL
Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
NCI-H322M GI50
21.7 μM
Compound: 1; PTL
Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
NCI-H460 GI50
18.8 μM
Compound: 1; PTL
Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
NCI-H460 IC50
9.6 μM
Compound: Parthenolide
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
[PMID: 35090346]
NCI-H522 GI50
5.47 μM
Compound: 1; PTL
Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
OVCAR-3 GI50
17.4 μM
Compound: 1; PTL
Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
OVCAR-4 GI50
21.5 μM
Compound: 1; PTL
Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
OVCAR-5 GI50
34.1 μM
Compound: 1; PTL
Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
OVCAR-8 GI50
17.1 μM
Compound: 1; PTL
Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
PC-3 IC50
>10 μM
Compound: Parthenolide
Cytotoxicity against human PC-3 cells assessed as cell growth inhibition incubated for 68 hrs by MTT assay
Cytotoxicity against human PC-3 cells assessed as cell growth inhibition incubated for 68 hrs by MTT assay
[PMID: 34665635]
PC-3 IC50
13.01 μM
Compound: Parthenolide
Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 27232656]
RPMI-8226 GI50
8.2 μM
Compound: 1; PTL
Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
RPMI-8226 GI50
8.2 μM
Compound: Parthenolide
Growth inhibition of human RPMI-8226 cells
Growth inhibition of human RPMI-8226 cells
[PMID: 38107170]
RXF 393 GI50
12.2 μM
Compound: 1; PTL
Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
SF-268 GI50
25.1 μM
Compound: 1; PTL
Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
SF-295 GI50
28.9 μM
Compound: 1; PTL
Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
SF-539 GI50
18.9 μM
Compound: 1; PTL
Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
SK-MEL-2 GI50
16.2 μM
Compound: 1; PTL
Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
SK-MEL-28 GI50
21 μM
Compound: 1; PTL
Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
SK-MEL-28 IC50
4.9 μM
Compound: Parthenolide
Cytotoxicity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 68 hrs by MTT assay
Cytotoxicity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 68 hrs by MTT assay
[PMID: 34665635]
SK-MEL-5 GI50
17.4 μM
Compound: 1; PTL
Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
SK-OV-3 GI50
54.7 μM
Compound: 1; PTL
Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
SN12C GI50
22.8 μM
Compound: 1; PTL
Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
SNB-19 GI50
70.9 μM
Compound: 1; PTL
Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
SNB-75 GI50
48.4 μM
Compound: 1; PTL
Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
SW-620 GI50
14.5 μM
Compound: 1; PTL
Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
TK-10 IC50
6.4 μM
Compound: PTD
Growth inhibition of human TK10 cells measured after 24 hrs by SRB assay
Growth inhibition of human TK10 cells measured after 24 hrs by SRB assay
[PMID: 27448920]
U-251 GI50
41.5 μM
Compound: 1; PTL
Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
U-87MG ATCC IC50
4.86 μM
Compound: Parthenolide
Cytotoxicity against human U87MG cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human U87MG cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 27232656]
UACC-257 GI50
14.4 μM
Compound: 1; PTL
Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
UACC-62 GI50
16.8 μM
Compound: 1; PTL
Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
UACC-62 IC50
15 μM
Compound: PTD
Growth inhibition of human UACC62 cells measured after 24 hrs by SRB assay
Growth inhibition of human UACC62 cells measured after 24 hrs by SRB assay
[PMID: 27448920]
UO-31 GI50
41.9 μM
Compound: 1; PTL
Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
[PMID: 28525840]
In Vitro

Parthenolide (PTL) has a dose-dependent growth inhibition effect on NSCLC cells Calu-1, H1792, A549, H1299, H157, and H460. Parthenolide can induce cleavage of apoptotic proteins such as CASP8, CASP9, CASP3 and PARP1 both in concentration- and time-dependent manner in tested lung cancer cells, indicating that apoptosis is trigged after Parthenolide exposure. In addition to induction of apoptosis, Parthenolide also induces G0/G1 cell cycle arrest in a concentration-dependent manner in A549 cells and G2/M cell cycle arrest in H1792 cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Only Parthenolide, the HDAC inhibitor with anti-inflammatory features, displayed a potent anti-apoptotic effect in Phb1 KO hepatocytes. Indeed, TSA and Parthenolide-treated hepatocytes showed increased levels of FXR, and reduced levels of CYP7A1, HDAC4, TNFα, TRAIL and Bax suggesting a less toxic effect of bile acids as a results of specific HDAC inhibition, resulting in the attenuation of the Phb1 KO hepatocytes apoptotic response. Importantly, Parthenolide exerts a protective effect from the liver injury after BDL in Phb1 KO mice. Indeed, Parthenolide treatment results in a reduction of the mortality rate of this mice after BDL associated with a lower apoptotic response as revealed by a reduction of necrotic areas, Tunel-staining, as well as decreased ALT (8431±957 vs.4225±210 U/L) and AST (4805±300 vs.2242±438 U/L) activities compared to control Phb1 KO mice[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique
Masse moléculaire

248.32

Formule

C15H20O3

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C/C1=C\CC[C@@](C)(O2)[C@H]2[C@@H](OC(C3=C)=O)[C@H]3CC1

Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvant et solubilité
In Vitro: 

DMSO : ≥ 100 mg/mL (402.71 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : < 0.1 mg/mL (insoluble)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.0271 mL 20.1353 mL 40.2706 mL
5 mM 0.8054 mL 4.0271 mL 8.0541 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (10.07 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

  • Protocol 2

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (8.38 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Pureté et documentation
Références

Vous serez peut-être également intéressé par les produits suivants :



Référence
Description
Cond.
Prix HT
HY-11109-10mg
 10mg 
HY-15816-5mg
 5mg 
HY-13687-10mg
 10mg